Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
FDA Approves First Drug for Lou Gehrig's Disease
Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica.
Minocycline up-regulates the expression of brain-derived neurotrophic factor and nerve growth factor in experimental autoimmune encephalomyelitis.
Optic Neuritis Probably Induced by Isotretinoin.
Purified and synthetic Alzheimer's amyloid beta (Aβ) prions.
IL-1 signal affects both protection and pathogenesis of virus-induced chronic CNS demyelinating disease.
Rebound of disease activity during pregnancy after withdrawal of fingolimod.
In Vivo Brain MR Imaging at Subnanoliter Resolution: Contrast and Histology.
B cells and antibodies in multiple sclerosis pathogenesis and therapy.
Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy.
Dalfampridine Improves Sensorimotor Function in Rats With Chronic Deficits After Middle Cerebral Artery Occlusion.
Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid β-induced memory impairment.
Multiple sclerosis and stress.
Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation.
[Lyme disease in patients with multiple sclerosis: clinical, diagnostic and therapeutic features.]
Distribution of JC polyomavirus genotypes in Tunisian renal transplant recipients between January 2008 and January 2011.
Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc.
Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
France Banned AB Science Drug Studies Because of Side Effects
Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.
Pain Research Forum: application of scientific social media frameworks in neuroscience.
[Side-effects of glucocorticosteroids in multiple sclerosis: a case report of a patient with global amnesia.]
Fingolimod for multiple sclerosis: a review for the specialist nurse.
Pages
« first
‹ previous
…
195
196
197
198
199
200
201
202
203
…
next ›
last »